SK Biopharmaceuticals Establishes Radiopharmaceuticals Division...Carries Out 2026 Organizational Restructuring

Choi Yoonjung Appointed as Head of Strategy Division

On December 4, SK Biopharmaceuticals announced that it has carried out an organizational restructuring for 2026, including the establishment of a Radiopharmaceuticals Division.

This restructuring was implemented to proactively respond to the changing global business environment and to strengthen core functions and execution capabilities centered on future growth drivers. The changes will take effect on January 1 of next year.

To accelerate the radiopharmaceuticals (RPT) business, which has emerged as a future growth modality, the company established the RPT Division. The RPT Division is an organization equipped with end-to-end operational functions, including securing raw materials and isotopes, discovering and conducting preclinical development of pipelines, and global business development. By establishing the Radiopharmaceuticals Division, the company aims to foster the RPT business as a core growth driver.

In addition, as the importance of future strategic direction and execution has increased, Choi Yoonjung, who has led the existing Business Development Division, has been appointed as Head of the Strategy Division. The Strategy Division will integrate the company’s core decision-making functions, including establishing mid- to long-term company-wide strategies, managing the business portfolio, promoting global growth strategies, and reviewing new businesses, thereby enhancing the alignment and speed of future strategy execution.

Through this organizational restructuring, SK Biopharmaceuticals plans to strengthen its competitiveness in the global market and solidify its foundation for balanced growth in new drug development and new businesses.

This content was produced with the assistance of AI translation services.